Navigation Links
U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain
Date:11/9/2009

Neurologists will use funds to move lab findings into human therapy for difficult-to-treat condition that involves pain from nerve damage

ANN ARBOR, Mich., Nov. 9 /PRNewswire-USNewswire/ --Researchers from the University of Michigan Department of Neurology have received a $1.8 million grant to develop a novel therapy for neuropathic pain, a difficult-to-treat condition in which patients experience pain because of damage to nerve without obvious tissue injury.

In previously published studies, these investigators have found that gene transfer to sensory nerves using a modified herpes simplex virus-based vector effectively reduced pain-related behaviors in rodents with nerve damage caused by trauma or diabetes. A gene transfer vector is an agent used to carry genes into cells.

The newly awarded grant from the Department of Veterans Affairs will allow the investigators to produce and certify a human grade vector that will then be tested in patients with pain from nerve damage resulting from diabetes.

"This grant will allow us to take the critical step in translating laboratory findings into human therapy," says principal investigator David Fink, M.D., Robert Brear professor and chair of the Department of Neurology. Fink is also a staff neurologist at the VA Ann Arbor Healthcare System.

Fink and his collaborators have previously demonstrated that gene transfer vectors created from recombinant crippled herpes simplex viruses can be used to deliver genes to sensory nerves from application in the skin.

Fink is directing a phase 1 human trial on the first such vector carrying the gene for human preproenkephalin in patients with intractable pain from cancer. The second trial will test a vector carrying the gene for glutamic acid decarboxylase that has proven to be particularly effective in animal models of neuropathic pain.

"We are very excited to receive this grant," says co-investigator Dr. Marina Mata, M.D., also a professor of Neurology.

"We routinely create new vectors and produce them in the laboratory for animal studies, but in order to have a vector that is approved for human use requires a series of extraordinarily expensive steps. This grant should allow us to begin the human trial in patients with painful diabetic neuropathy within two years."

Construction of the vector will be carried out under contract by Diamyd, Inc. of Pittsburgh, PA. Diamyd is funding the phase 1 trial of the preproenkephalin vector, and has licensed the patents to the vector technology.

The researchers believe that the use of HSV vectors holds promise not only for the treatment of pain but also ultimately for the treatment of peripheral neuropathy itself.

Fink has received research funding from Diamyd related to the human trial of the preproenkephalin vector. He has no equity interest in nor any consulting agreements with Diamyd.

SOURCE University of Michigan Health System


'/>"/>
SOURCE University of Michigan Health System
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers show how to divide and conquer social network of cells
2. Connection between depression and osteoporosis detailed by Hebrew University researchers
3. Researchers find new way to attack inflammation in Graves eye disease
4. Jefferson researchers receive $3.9 million in Challenge grants
5. Childhood cancer survivors less likely to marry, Yale researchers find
6. Researchers unlock the sound of learning by linking sensory and motor systems
7. Researchers identify the 3 killer indicators that are even worse than high cholesterol
8. Researchers discover links between city walkability and air pollution exposure
9. High-definition colonoscopy detects more polyps, Mayo Clinic researchers say
10. Researchers find room design can enhance patient care
11. UC San Diego researchers reverse pulmonary arterial hypertension in mouse models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group ... Tournament held on June 20th at the Woodmont Country Club at 1201 Rockville ... an organization dedicated to helping service members that have been wounded in battle and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: